<DOC>
	<DOCNO>NCT00267514</DOCNO>
	<brief_summary>The purpose study determine sevelamer carbonate powder effective treatment control serum phosphorous level patient dialysis compare sevelamer hydrochloride tablet .</brief_summary>
	<brief_title>Study Demonstrate Equivalence Sevelamer Carbonate Powder Sevelamer HCl Tablets Haemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Receiving three time per week haemodialysis three month longer . Taking sevelamer hydrochloride alone ( e.g . use type phosphate binder concomitantly ) combination therapy ( e.g . use sevelamer hydrochloride calcium containing , metal phosphate binder concomitantly ) exceed total daily binder dose 14.4 g , least 60 day prior screen . Have follow document local laboratory measurement : 1 . Two recent consecutive serum phosphorus measurement ≥ 3.0 ≤ 7.0 mg/dL ( ≥ 0.96 ≤ 2.26 mmol/L ) within 60 day screen 2 . An recent iPTH measurement ≤ 900 pg/mL ( &lt; 99 pmol/L ) within 90 day screen 3 . A recent serum calcium ( adjust albumin ) measurement within normal range define local laboratory within 60 day screen Have follow central laboratory measurement : 1 . A serum phosphorus measurement ≥ 5.5 mg/dL ( ≥ 1.76 mmol/L ) Visit 2 ( Washout ) 2 . A serum iPTH measurement ≤ 800 pg/mL Visit 5 ( prior randomization ) 3 . A serum phosphorus measurement ≥ 3.0 ≤ 6.5 mg/dL ( ≥ 0.96 ≤ 2.08 mmol/L ) Visit 5 If vitamin D replacement calcimimetics therapy , stable dose least one month prior screen willing maintain dose throughout duration study , except safety reason . Willing maintain screening dose lipid medication duration study , except safety reason . Willing avoid intentional change diet fast dieting . If female childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study , include barrier method , hormone , intrauterine device ( IUDs ) . Willing stop calcium supplement prescribe investigator include multivitamin contain calcium . Willing refrain use aluminium , calcium , lanthanum , magnesium containing antacid throughout duration study unless prescribe investigator calcium supplement per protocol . Have level understanding willingness cooperate visit procedure , include telephone contact , describe consent study site personnel . Have poorly control diabetes mellitus hypertension , active vasculitis , HIV infection , clinically significant unstable medical condition ( defined investigator ) . Have active dysphagia , swallow disorder , bowel obstruction , severe gastrointestinal motility disorder . Have participate study investigational drug 30 day precede start screen period . Has active ethanol drug dependence abuse , exclude tobacco use . Have condition , , investigator 's opinion , prohibit patient 's participation study . If female , pregnant breastfeeding . Have evidence active malignancy except basal cell carcinoma skin . A history malignancy exclusion . Use antiarrhythmic antiseizure medication arrhythmia seizure disorder . Have know hypersensitivity sevelamer constituent . Have poor record compliance medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hemodialysis</keyword>
</DOC>